全文获取类型
收费全文 | 2666篇 |
免费 | 268篇 |
国内免费 | 191篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 17篇 |
妇产科学 | 29篇 |
基础医学 | 262篇 |
口腔科学 | 12篇 |
临床医学 | 134篇 |
内科学 | 236篇 |
皮肤病学 | 83篇 |
神经病学 | 91篇 |
特种医学 | 21篇 |
外科学 | 74篇 |
综合类 | 265篇 |
预防医学 | 38篇 |
眼科学 | 12篇 |
药学 | 1284篇 |
中国医学 | 421篇 |
肿瘤学 | 145篇 |
出版年
2024年 | 10篇 |
2023年 | 44篇 |
2022年 | 63篇 |
2021年 | 104篇 |
2020年 | 73篇 |
2019年 | 97篇 |
2018年 | 98篇 |
2017年 | 109篇 |
2016年 | 105篇 |
2015年 | 109篇 |
2014年 | 127篇 |
2013年 | 336篇 |
2012年 | 166篇 |
2011年 | 188篇 |
2010年 | 115篇 |
2009年 | 137篇 |
2008年 | 136篇 |
2007年 | 132篇 |
2006年 | 120篇 |
2005年 | 94篇 |
2004年 | 91篇 |
2003年 | 72篇 |
2002年 | 67篇 |
2001年 | 52篇 |
2000年 | 50篇 |
1999年 | 39篇 |
1998年 | 46篇 |
1997年 | 45篇 |
1996年 | 45篇 |
1995年 | 37篇 |
1994年 | 43篇 |
1993年 | 32篇 |
1992年 | 32篇 |
1991年 | 20篇 |
1990年 | 27篇 |
1989年 | 22篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1978年 | 1篇 |
排序方式: 共有3125条查询结果,搜索用时 15 毫秒
1.
目的 研究乙型肝炎病毒(HBV)自身增强子I(enhancerI,ENHI)对HBV DNA疫苗免疫应答的影响。方法 采用PCR法以HBVadr亚型全基因DNA序列为模板分别扩增表面抗原(HBsAg)和HBsA-ENHI基因片段,重组到载体VR1012中,构建两种HBV DNA疫苗,转染CADS-7细胞及HepG2细胞并免疫BALB/c小鼠。采用蛋白印迹、ELISA、ELISPOT等方法检测其在COS-7和HepG2细胞内的表达及小鼠的体液及细胞免疫应答效果。结果 转染的HepG2和COS-7细胞均表达HBsAg;连接ENHI的HBV DNA疫苗转染HepG2细胞后HBsAg表达量明显升高,两种疫苗转染COS-7细胞表达HBsAg无明显差异;免疫小鼠后第2周产生HBsAb及HBsAg特异性细胞毒T淋巴细胞(CTL),两种疫苗免疫产生的HBsAb及HBsAg特异性CTL无明显差异。结论ENHI可使HBV DNA疫苗转染HepG2细胞表达HBsAg明显增加,对转染COS-7细胞表达HBsAg及接种BALB/C小鼠引起的免疫应答无明显影响。 相似文献
2.
A flow-through finite-dose diffusion cell has been designed for use in transdermal drug delivery research. The diffusion cell consists of an upper donor chamber and a lower receiver compartment through which a continuous supply of fresh solvent flows. The flow is directed to an automatic fraction collector. To validate the flow-through cell, its performance was compared directly against that of a conventional single-reservoir Franz cell. Homologous alkyl p-aminobenzoates were diffused through dimethylpolysiloxane membranes, and permeability coefficients increased with increasing chain length, reaching a plateau at the butyrate ester for both types of cells. This behavior suggests a shift from membrane-controlled diffusion to boundary layer control. Permeation of the butyrate and valerate compounds was significantly faster when the flow-through cell was used, suggesting that better mixing is obtained through the flow-through cell design. Considering the advantages offered in terms of time and labor saved through its use, the flow-through cell with automatic fraction collector appears to be a viable alternative to the conventional Franz cell. 相似文献
3.
Michiko Oka Y. Itoh Shigeru Tatsumi F.-H. Ma Yojiro Ukai Yoshiaki Yoshikuni Kiyoshi Kimura 《Naunyn-Schmiedeberg's archives of pharmacology》1997,356(2):189-196
The effect of (+)-5-oxo-D-prolinepiperidinamide monohydrate (NS-105), a novel cognition enhancer, on adenylate cyclase activity
was investigated in cultured neurons of the mouse cerebral cortex. NS-105 (10–7 and 10–6 M) inhibited forskolin-stimulated cyclic AMP formation, an action that was dependent on pertussis toxin-sensitive G proteins.
Conversely, in pertussis toxin-pretreated neurons, NS-105 (10–7 –10–5 M) significantly enhanced the forskolin-stimulated cyclic AMP formation, and this action was completely reversed by cholera
toxin. A metabotropic glutamate receptor agonist (1S, 3R)-1-aminocyclopentane-1, 3-dicarboxylic acid (1S, 3R-ACPD) produced
similar bi-directional actions on the cyclic AMP formation. Both of these inhibitory and facilitatory actions of NS-105 and
1S, 3R-ACPD were blocked by L(+)-2-amino-3-phosphopropinoic acid (L-AP3). NS-105 (10–6 M) and 1S, 3R-ACPD (10–4 M) significantly enhanced isoproterenol- and adenosine-stimulated cyclic AMP formation. The enhancement of such Gs-coupled
receptor agonists-stimulated cyclic AMP formation was also produced by quisqualate but not by L(+)-2-amino-4-phosphonobutanoate
(L-AP4). The phosphoinositides hydrolysis was enhanced by 1S, 3R-ACPD (10–4 M) but not by NS-105 (10–6 M), however, 1S, 3R-ACPD-induced increase in phosphoinositides turnover was attenuated by NS-105. These findings suggest
that NS-105 stimulates metabotropic glutamate receptor subclasses that are coupled both negatively and positively to adenylate
cyclase, but it acts as an antagonist at the receptor subclasses that are linked to phosphoinositides hydrolysis.
Received: 3 February 1997 / Accepted: 25 April 1997 相似文献
4.
5.
Gene expression regulation and cancer 总被引:1,自引:0,他引:1
6.
T. O. Klemsdal H. H. Mundal K. Gjesdal 《European journal of clinical pharmacology》1996,51(3-4):227-230
Objective:
We examined the relationship between tolerance development, counterregulatory responses and arterial vasodilating effects
evaluated by digital pulse plethysmography.
Methods:
Twenty patients with stable angina pectoris were exercise tested before, after 2 and after 24 h of open nitrate patch treatment.
Results:
The effects observed after 2 h of treatment on exercise duration, ST-segment depression, blood pressure and heart rate were
lost in most individuals after 24 h. In contrast, the effects on the arterial pulse curves persisted after 24 h, with a mean
change from baseline of 29%, compared to 33% at 2 h. After 24 h, a significant decrease in haematocrit and an increase in
body weight were observed. The haematocrit changes correlated with the loss of clinical efficacy (r =0.57 for ST-segment depression, and r =0.54 for exercise duration).
Conclusion:
Clinical nitrate tolerance may be observed despite maintenance of the arterial vasodilating effects, and tolerance is more
related to plasma volume expansion as a counterregulatory mechanism.
Received: 28 February 1996/Accepted in revised form: 5 July 1996 相似文献
7.
应用我室建立的化学发光自显影技术检测鸭沙门氏菌。用酶标抗体与硝酸纤维素膜上固定的细菌结合,再同发光底物溶液作用,使X线胶片感光,根据胶片上的黑斑进行半定量,可检出100个菌。其检测特异性好,约2小时即可出报告。 相似文献
8.
Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment 总被引:2,自引:0,他引:2
M. Cortellaro T. Nencioni C. Boschetti S. Ortolani F. Buzzi B. Francucci M. P. Caraceni P. Abelli F. Polvani C. Zanussi 《European journal of clinical pharmacology》1991,41(6):555-559
Summary In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient.Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors.Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels. 相似文献
9.
Sixty-four patients with persistent asthma receiving 200 to 800 μ g of fluticasone propionate daily were enrolled in this switchover study. The patients applied a tulobuterol patch 2 mg every 24 hours for 4 weeks followed by inhalation of salmeterol 100 μ g bid for 4 weeks. The mean values for morning and evening peak expiratory flow improved significantly compared with baseline during the 4 weeks of tulobuterol patch treatment. Further improvement was seen on switching to salmeterol treatment, which was significant even in the first week, and continued until the final week of the study. Use of salmeterol alone resulted in a significant increase in the percentage of forced expiratory volume in 1 second %FEV1 from baseline, with 51% of patients feeling that the treatment was effective (vs. 37% on tulobuterol). These data suggest that salmeterol can achieve better control in asthmatic patients after switching from using tulobuterol patches. 相似文献
10.
Nir Giladi Babak Boroojerdi Amos D Korczyn David J Burn Carl E Clarke Anthony H V Schapira 《Movement disorders》2007,22(16):2398-2404
Rotigotine is a new, non-ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine, ropinirole, or placebo. The titration period was up to 13 weeks, and there was a minimum dose-maintenance period of 24 weeks for ropinirole and 33 weeks for rotigotine. The primary endpoint was the proportion of patients with a minimum of 20% decrease in the combined Unified Parkinson's Disease Rating Scale Part II and Part III scores. The responder rate in the rotigotine group was significantly higher than in the placebo group (52% vs. 30%, P < 0.0001). Transdermal rotigotine at doses < or =8 mg/24 h did not show noninferiority to ropinirole at doses < or =24 mg/day. In a post-hoc subgroup analysis, rotigotine < or =8 mg/24 hours had a similar efficacy to ropinirole at doses < or =12 mg/day. The rotigotine transdermal patch was well tolerated. The most common adverse events were application-site reactions, nausea, and somnolence. Application-site reactions were predominantly mild or moderate in intensity. In conclusion, the rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease. 相似文献